论文部分内容阅读
目的 :探讨血清基质金属蛋白酶MMP-9及其抑制剂TIMP-1在乳腺癌患者术前血清中的表达与临床病理特征的关系。方法 :收集52例乳腺肿瘤患者术前血清,通过ELISA方法检测9例良性肿瘤患者与43例浸润性乳腺癌患者血清中MMP-9和TIMP-1的含量并计算二者比值,用免疫组化技术检病变组织中MMP-9和TIMP-1的表达。结果 :与良性肿瘤相比,MMP-9与TIMP-1蛋白表达在术前乳腺癌患者血清中的表达均有显著性升高;对于乳腺癌患者而言,术前血清中MMP-9、TIMP-1的浓度与MMP-9/TIMP-1的比值与患者的TNM分期、肿瘤长度、淋巴结累及之间具有统计学差异,但与患者的年龄、分级无关;MMP-9和TIMP-1二者的浓度之间并无相关性;血清中MMP-9和TIMP-1的浓度与组织蛋白的表达呈正相关。结论 :检测术前血清中MMP-9与TIMP的表达有潜力作为良恶性肿瘤鉴别的指标之一;监测乳腺癌患者血清MMP-9和TIMP-1的表达有助于确定肿瘤的转移情况,并对预后的判断具有参考意义。
Objective: To investigate the relationship between the expression of serum matrix metalloproteinase-9 and its inhibitor TIMP-1 in preoperative serum of breast cancer patients and the clinicopathological characteristics. Methods: Serum levels of MMP-9 and TIMP-1 in serum of 9 patients with benign tumor and 43 patients with invasive breast cancer were detected by ELISA. The ratio of serum MMP-9 and TIMP-1 was calculated by immunohistochemistry The technique examines the expression of MMP-9 and TIMP-1 in varying tissues. Results: Compared with benign tumors, the expression of MMP-9 and TIMP-1 protein in serum of preoperative breast cancer patients were significantly increased. For breast cancer patients, the levels of MMP-9, TIMP There was a significant difference between the ratio of MMP-9 / TIMP-1 and the ratio of TNM stage, tumor length and lymph node involvement, but not with the age and grade of the patients. Both MMP-9 and TIMP-1 There was no correlation between the concentration of MMP-9 and TIMP-1 in serum and the expression of tissue protein. Conclusion: Detecting the expression of MMP-9 and TIMP in preoperative serum has the potential as one of the differential diagnosis of benign and malignant tumors. Monitoring the expression of serum MMP-9 and TIMP-1 in breast cancer patients is helpful to determine the metastasis of tumor The judgment of prognosis has reference value.